UMIN ID: UMIN000055507
Registered date:01/10/2024
Glycaemic control efficacy of switching from semaglutide to tirzepatide in subjects with type 2 diabetes
Basic Information
| Recruitment status | Pending |
|---|---|
| Health condition(s) or Problem(s) studied | Type 2 Diabetes |
| Date of first enrollment | 2024/10/01 |
| Target sample size | 30 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Tirzepatide is initiated at a dose of 2.5 mg once weekly, and the doses is increased by 2.5 mg every 4 weeks until the assigned dose. |
Outcome(s)
| Primary Outcome | The primary end point was the change in the glycated hemoglobin level from beseline to week 52. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Key exclusion criteria were type 1 diabetes;and a histoly of any of the following:nonproliferatine diabtetic retinopathy that warranted urgent treatment,proliferative diabetic reitopathy, or diabetic maculopathy. |
Related Information
| Primary Sponsor | Saitama Medical University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Saitama Medical University Hospital |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Susumu Kurihara |
| Address | 38 MOROHONGO,MOROYAMA-MACHI,IRUMA-GUN,SAITAMA Japan 350-0495 |
| Telephone | 049-276-1204 |
| sk3512@saitama-med.ac.jp | |
| Affiliation | Saitama Medical University Hospital Department of Endocrinology and Diabetes |
| scientific contact | |
| Name | Akira Shimada |
| Address | 38 MOROHONGO,MOROYAMA-MACHI,IRUMA-GUN,SAITAMA Japan |
| Telephone | 049-276-1204 |
| asmd@saitama-med.ac.jp | |
| Affiliation | Saitama Medical University Hospital Department of Endocrinology and Diabetes |